The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial.

RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This approach positions Resalis to potentially be at the forefront of next-generation therapies in metabolic diseases, they state.

“The therapeutic landscape for obesity is rapidly evolving, and Sanofi’s investment highlights the potential of our approach. As we prepare to initiate a Phase 1 clinical trial for RES-010, this investment not only validates the robust data we’ve generated so far but also positions us to quickly advance through Phase 2 trials, bringing us closer to offering a potentially transformative treatment for patients living with obesity. We believe this will be a catalyst for further interest in this growing market,” says Alessandro Toniolo, CEO of Resalis Therapeutics.